Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy

Abstract

Introduction

Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients.

Materials and methods

In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS.

Results

218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI ≤ 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI > 48 months (3-year OS 73.5%).

Conclusions

Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. Agolli L, Bracci S, Nicosia L et al. (2017) Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer 16(1):58–64. https://doi.org/10.1016/j.clcc.2016.07.004

  2. Ahmed KA, Caudell JJ, El-Haddad G et al (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol 95(5):1399–1404. https://doi.org/10.1016/j.ijrobp.2016.03.050

  3. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66(4):683–691. https://doi.org/10.1136/gutjnl-2015-310912

  4. Barry A, Wong R, Dawson LA (2019) The management of colorectal cancer liver metastases: the radiation oncology viewpoint. Int J Radiat Oncol 103(3):540–541. https://doi.org/10.1016/j.ijrobp.2018.10.010

  5. Breiman L, Friedman J, Olshen R, Stone C (1984) Classification and regression trees. Chapman and Hall, Wadsworth, New York

  6. Casiraghi M, De Pas T, Brambilla D et al (2011) A 10-year single-center experience on 708 lung metastasectomies the evidence of the “international registry of lung metastases”. J Thorac Oncol 6(8):1373–1378

  7. Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases. Cancer 117(17):4060–4069. https://doi.org/10.1002/cncr.25997

  8. Choti MA (2014) Liver-directed treatments for metastatic colorectal cancer. Curr Treat Options Oncol 15(3):456–464. https://doi.org/10.1007/s11864-014-0297-1

  9. Dell’Acqua V, Surgo A, Kraja F et al (2019) Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. Clin Exp Metastasis 36(4):331–342. https://doi.org/10.1007/s10585-019-09976-z

  10. Fode MM, Høyer M (2015) Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol 114(2):155–160. https://doi.org/10.1016/j.radonc.2014.12.003

  11. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LHBM (1997) Liver resection for colorectal metastases. J Clin Oncol 15(3):938–946

  12. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 230(3):309. https://doi.org/10.1097/00000658-199909000-00004

  13. Franzese C, Comito T, Toska E et al (2018a) Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. https://doi.org/10.1016/j.radonc.2018.10.024

  14. Franzese C, Comito T, Clerici E et al (2018b) Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. J Cancer Res Clin Oncol 144(9):1777–1783. https://doi.org/10.1007/s00432-018-2692-7

  15. Hong JC, Ayala-Peacock DN, Lee J et al (2018) Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PLoS One 13(4):e0195149. https://doi.org/10.1371/journal.pone.0195149

  16. Høyer M, Swaminath A, Bydder S et al (2012) Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol. 82(3):1047–1057. https://doi.org/10.1016/j.ijrobp.2011.07.020

  17. Jackson WC, Tao Y, Mendiratta-Lala M et al (2018) Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol 100(4):950–958. https://doi.org/10.1016/j.ijrobp.2017.12.014

  18. Joo JH, Park JH, Kim JC et al (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99(4):876–883. https://doi.org/10.1016/j.ijrobp.2017.07.030

  19. Jung J, Song SY, Kim JH et al (2015) Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol 10:238. https://doi.org/10.1186/s13014-015-0546-x

  20. Kobiela J, Spychalski P, Marvaso G et al. (2018) Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol 129:91–101

  21. Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5

  22. Park C, Papiez LZS et al (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy: in regard to Parks et al. (Int J Radiat Oncol Biol Phys 2008;70:847–852). Int J Radiat Oncol Biol Phys 70:847–852. https://doi.org/10.1016/j.ijrobp.2008.08.032

  23. Tanadini-Lang S, Rieber J, Filippi AR et al (2017) Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol 123(2):182–188. https://doi.org/10.1016/j.radonc.2017.01.003

  24. Van den Begin R, Engels B, Collen C et al (2019) The METABANK score: a clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. Radiother Oncol 133:113–119. https://doi.org/10.1016/j.radonc.2019.01.001

  25. Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJM, Langendijk JA (2013) Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 107(3):409–413. https://doi.org/10.1016/j.radonc.2013.05.024

Download references

Funding

No funding was used for the present work.

Author information

Correspondence to Ciro Franzese.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Statistical analysis: Ciro Franzese.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Franzese, C., Comito, T., Franceschini, D. et al. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. J Cancer Res Clin Oncol (2020). https://doi.org/10.1007/s00432-020-03148-3

Download citation

Keywords

  • SBRT
  • Stereotactic body radiation therapy
  • Colorectal cancer
  • Oligometastases
  • Radiotherapy
  • Recursive partitioning analysis
  • RPA